Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 239-248

  Hamerschlak, N ^a   Rodrigues, M ^a   Moraes, D A ^b   Oliveira, M C ^b   Stracieri, A B P L ^b   Pieroni, F ^b   Barros, G M N ^b   Madeira, M I A ^b   Simes, B P ^b   Barreira, A A ^b   Brum, D G ^b   Ribeirao A A F ^a   Kutner, J M ^a   Tylberi, C P ^a   Porto, P P ^a   Santana, C L ^c   Neto, J Z ^d   Barros, J C ^b   Paes, A T ^a   Burt, R K ^e   Oliveira, E A ^b   Mastropietro, A P ^b   Santos, A C ^f   Voltarelli, J C ^b   more..

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Araujo Jorge Hospital   (Brazil)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Ribeirao Preto School of Medicine   (Brazil)

Author keywords

BEAM regimen; CY; Hematopoietic SCT; Hematopoietic stem cell mobilization; Multiple sclerosis

Indexed keywords

ACICLOVIR; BUSULFAN; CARMUSTINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GADOLINIUM PENTETATE MEGLUMINE; GENZYME; LYMPHOCYTE ANTIBODY; MELPHALAN; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; TIABENDAZOLE; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ARTICLE; CARDIOTOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG HYPERSENSITIVITY; EXPANDED DISABILITY STATUS SCALE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LENGTH OF STAY; LUNG EMBOLISM; LUNG HEMORRHAGE; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SEPSIS; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; URINARY TRACT INFECTION;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; ETOPOSIDE; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORSES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RABBITS; TRANSPLANTATION CONDITIONING;

EID: 76749166185     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.127     Document Type: Article

References (57)

1. Hafler DA. Multiple sclerosis. J Clin Invest 2004; 113: 788-794.
2. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3: 291-301. (Pubitemid 135706608)
3. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3: 104-110.
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
5. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
6. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-260.
7. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
8. Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol 2009; 16: 424-426.
9. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
10. Ikehara S, Yasumizu R, Inaba M, Izui S, Hayakawa K, Sekita K et al. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 1989; 86: 3306-3310.
11. van Bekkum DW. Autologous stem cell transplantation for treatment of autoimmune diseases. Stem Cells 1999; 17: 172-178.
12. Bekkum DW. Immune ablation and stem-cell therapy in autoimmune diseases. Experimental basis for autologous stemcell transplantation. Arthritis Res 2000; 2: 281-284.
13. van Bekkum DW. Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases. J Leukoc Biol 2002; 72: 609-620.
14. van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 1995; 16: 343-351.
15. Burt RK, Traynor AE. Hematopoietic stem cell transplantation: a new therapy for autoimmune diseases. Oncologist 1999; 4: 77-83.
16. Burt RK, Padilla J, Dal Canto MC, Miller SD. Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Blood 1999; 94: 2915-2922.
17. Burt RK, Padilla J, Begolka WS, Canto MC, Miller SD. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998; 91: 2609-2616.
18. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol 2000; 20: 10-16.
19. Herrmann MM, Gaertner S, Stadelmann C, van den Brandt J, Böscke R, Budach W et al. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood 2005; 106: 1875-1883.
20. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-816.
21. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997; 20: 631-638.
22. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995; 16: 1-6.
23. Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998; 21: 537-541.
24. Blanco Y, Saiz A, Carreras E, Graus F. Autologous haematopoietic-stem- cell transplantation for multiple sclerosis. Lancet Neurol 2005; 4: 54-63.
25. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002; 249: 1088-1097.
26. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006; 12: 814-823.
27. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6: 563-575.
28. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102: 2364-2372.
29. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005; 105: 2601-2607.
30. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102: 2373-2378.
31. Burt RK, Loh Y, Cohen B, Stefosky D, Balabanov R, Katsamakis G et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 244-253.
32. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J et al. Non-myeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535.
33. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F et al. Autologous non-myeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297: 1568-1576. (Pubitemid 46588370)
34. Oyama Y, Barr WG, Statkute L, Corbridge T, Gonda EA, Jovanovic B et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007; 40: 549-555.
35. Carreras E, Saiz A, Marín P, Martínez C, Rovira M, Villamor N et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003; 88: 306-314.
36. Kozák T, Havrdová E, Pit'ha J, Gregora E, Pytlík R, Maaloufová J et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant Proc 2001; 33: 2179-2181.
37. Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meché FG et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 46-50.
38. Shevchenko YL, Novik AA, Kuznetsov AN, Afanasiev BV, Lisukov IA, Kozlov VA et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008; 36: 922-928.
39. Saiz A, Blanco Y, Berenguer J, Gó mez-Choco M, Carreras E, Arbizu T et al. Resultado clínico a 6 años del trasplante autó logo de progenitores hematopoyéticos en la esclerosis mú ltiple. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis]. Neurologia 2008; 23: 405-407.
40. Kozak T, Havrdova E, Pitha J, Mayerova K, Novakova L, Trneny M et al. Immunoablative therapy with autologous PBPC transplantation in the treatment of poor-risk multiple sclerosis. Bone Marrow Transplant 2008; 41(Suppl 1): S18 (abstract). Available from: http://registration.akm.ch/einsicht. php?XNABSTRACT-ID=68025&XNSPRACHE-ID=2&X NKONGRESS-ID=69&XNMASKEN- ID=900, Accessed in 2009 (Mar 27).
41. Saccardi R, Mancardi G, Bosi A, Bruzzi P, Di Bartolomeo P, Donelli A et al. Autologous HSCT for severe progressive multiple sclerosis in the Italian prospective, multicentre GITMONeuro trial: long-term follow-up. Bone Marrow Transplant 2008; 41(Suppl 1): S17 (abstract). Available from: http://registration. akm.ch/einsicht.php?XNABSTRACT-ID=68382&XNSPRAC HE-ID=2&XNKONGRESS-ID=69&XNMASKEN-ID=900. Accessed in 2009 (Mar 27).
42. Freedman MS, Atkins HL, Arnold DL, Bar-Or A, on behalf of the Canadian BMT Study Group. Immune ablation and autologous stem cell transplantation for aggressive multiple sclerosis: interim 5-year report. Mult Scler 2007; 13 (Supp 2): S22 (abstract). Available from: http://registration.akm.ch/ einsicht.php?XNABSTRACT-ID=52501&XNSPRACHE-ID =2&XNKONGRESS-ID= 63&XNMASKEN-ID=900. Accessed in 2009 (Mar 27).
43. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006; 20: 485-489.
44. Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006; 84: 276-281.
45. Xu J, JI B, Su L, Dong HQ, Sun XJ, Liu CY. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl) 2006; 119: 1851-1855.
46. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006; 54: 3750-3760.
47. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 2006; 107: 1696-1702.
48. Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005; 52: 1555-1563.
49. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214-223.
50. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
51. Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol 2000; 247: 376-382.
52. Rowley SD. Hematopoietic stem cell cryopreservation. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation, 2nd edn. Blackewell Science: Boston, MA, USA, 1999, pp 481-492.
53. Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS centers consensus guidelines. AJNR Am J Neuroradiol 2006; 27: 455-461.
54. Barkhof F, Filippi M, van Waesberghe JH, Molyneux P, Rovaris M, Lycklamaà Nijeholt G et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997; 49: 1682-1688.
55. Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D et al. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 2005; 62: 860-864.
56. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008; 7: 626-636.
57. Mancardi GL, Saccardi R, Filippi M, Gualandi F, Murialdo A, Inglese M et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001; 57: 62-68. (Pubitemid 32634851)